Keytruda improves PFS in classical Hodgkin lymphoma
The drug went head-to-head with brentuximab vedotin (BV) – also sold as Adcetris by Seattle Genetics.
Read More
Tag: KEYNOTE
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
